3 documents found, page 1 of 1
Broad-spectrum antivirals against viral fusion
Vigant, Frederic; Santos, Nuno C.; Lee, BenhurEffective antivirals have been developed against specific viruses, such as HIV, Hepatitis C virus and influenza virus. This ‘one bug–one drug’ approach to antiviral drug development can be successful, but it may be inadequate for responding to an increasing diversity of viruses that cause significant diseases in humans. The majority of viral pathogens that cause emerging and re emerging infectious diseases are ...
The rigid amphipathic fusion Inhibitor dUY11 acts through photosensitization of...
Vigant, Frederic; Hollmann, Axel; Lee, Jihye; Santos, Nuno C.; Jung, Michael E.; Lee, BenhurRigid amphipathic fusion inhibitors (RAFIs) are lipophilic inverted-cone-shaped molecules thought to antagonize the membrane curvature transitions that occur during virus-cell fusion and are broad-spectrum antivirals against enveloped viruses (Broad-SAVE). Here, we show that RAFIs act like membrane-binding photosensitizers: their antiviral effect is dependent on light and the generation of singlet oxygen (1O2),...
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
Vigant, Frederic; Lee, Jihye; Hollmann, Axel; Tanner, Lukas B.; Ataman, Zeynep Akyol; Yun, Tatyana; Shui, Guanghou; Aguilar, Hector C.; Zhang, DongLJ001 is a lipophilic thiazolidine derivative that inhibits the entry of numerous enveloped viruses at non-cytotoxic concentrations (IC50≤0.5 mM), and was posited to exploit the physiological difference between static viral membranes and biogenic cellular membranes. We now report on the molecular mechanism that results in LJ001’s specific inhibition of viruscell fusion. The antiviral activity of LJ001 was light...